A malignant bone marrow disease in which blood-forming cells are arrested in early development. NEUPOGEN® has been approved for treatment of AML since 1998.
As scientists who evolve with technology we treat innovation as a way of life, a life we dedicate to improvement and advancement of Safety, Health and Environment.
